Catalyst Pharmaceuticals, Inc.

NasdaqCM:CPRX Stock Report

Market Cap: US$2.4b

Catalyst Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Catalyst Pharmaceuticals has a total shareholder equity of $608.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $706.4M and $97.7M respectively. Catalyst Pharmaceuticals's EBIT is $85.9M making its interest coverage ratio -10.6. It has cash and short-term investments of $375.7M.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-10.6x
CashUS$375.69m
EquityUS$608.66m
Total liabilitiesUS$97.71m
Total assetsUS$706.36m

Recent financial health updates

No updates

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27
Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13
Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition

Sep 12

Catalyst Pharma ends momentum as Roth downgrades

Aug 24

Financial Position Analysis

Short Term Liabilities: CPRX's short term assets ($474.4M) exceed its short term liabilities ($92.3M).

Long Term Liabilities: CPRX's short term assets ($474.4M) exceed its long term liabilities ($5.4M).


Debt to Equity History and Analysis

Debt Level: CPRX is debt free.

Reducing Debt: CPRX has not had any debt for past 5 years.

Debt Coverage: CPRX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CPRX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies